SueWallSt

Dive into the NuScale Power $SMR controversy as we break down a high stakes securities class action involving nuclear energy, small modular reactors, and alleged misleading disclosures about key partner ENTRA1. This episode is for investors, traders, and anyone following energy stocks, clean energy, and stock market risk. Expect deep dives, case analysis, and sharp insights into financial reporting and investor transparency.

Visit ZLK.com for more info.

Add our WhatsApp Channel

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Dive into the explosive Ostin Technology Group $OST case as we break down an alleged billion dollar pump and dump scheme, shareholder lawsuit, and federal charges. This episode is for retail investors, traders, and anyone interested in stock market fraud, securities litigation, and financial news. Expect deep dives, real case analysis, and engaging discussion on market manipulation and investor risk.

Visit ZLK.com for more info.

Add our WhatsApp Channel

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PYPL PayPal and its ambitious Branded Checkout growth targets. We examine Investor Day projections, twenty percent plus long term earnings goals, Venmo and buy now pay later expansion, slowing transaction payment volume growth, withdrawal of twenty twenty seven guidance, the CEO departure, and the twenty percent stock drop that followed. This deep dive is for fintech investors, growth stock traders, and anyone tracking earnings volatility, corporate governance, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventeen percent stock drop that followed. This deep dive is for biotech investors, gene therapy traders, and anyone following FDA risk, clinical trial safety, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three hundred forty five million dollar stock offering, and the forty nine percent stock drop. This deep dive is for biotech investors, healthcare traders, and anyone following gene therapy stocks, FDA approvals, clinical trial risk, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $KD Kyndryl and alleged misstatements about internal controls over financial reporting. We examine IT general control weaknesses, cash flow misstatements, the late Form 10 Q filing, SEC Division of Enforcement inquiry, executive departures, and the fifty five percent stock drop that followed. This deep dive is for tech investors, corporate governance watchers, and anyone tracking accounting risk and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $INO Inovio Pharmaceuticals and its accelerated approval hopes for INO 3107 and the CELLECTRA device. We examine the Biologics License Application delay, manufacturing issues, FDA standard review decision, stock offerings, and the twenty four percent stock drop that followed. This deep dive is for biotech investors, healthcare traders, and anyone following FDA approvals, DNA medicines, regulatory risk, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PSFE Paysafe and alleged undisclosed concentration risk in its ecommerce business. We examine revenue guidance, credit loss reserves, chargebacks tied to a high risk merchant, Merchant Category Code exposure, sponsor bank pressure, and the twenty seven percent stock drop that followed. This deep dive is for retail investors, fintech traders, and anyone tracking payment processing stocks, earnings volatility, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $TCPC BlackRock TCP Capital and alleged misstatements about net asset value, portfolio health, and non accrual investments. We examine NAV declines from ten dollars to near seven dollars, rising unrealized losses, restructuring efforts, and the sharp stock drops that followed. This deep dive is for income investors, BDC shareholders, and anyone tracking dividend stocks, credit risk, valuation practices, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $MREO Mereo BioPharma and its Phase Three ORBIT and COSMIC trials for setrusumab in osteogenesis imperfecta. We break down Phase Two bone mineral density data, missed fracture reduction endpoints, interim analysis results, the eighty seven percent stock collapse, and alleged misleading statements about clinical confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, clinical trial risk, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel